The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of
O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083
improves overall survival (OS), compared to historical control, in the adjuvant or recurrent
Estimated Primary Completion Date
October 30, 2022
- Drug: VAL-083, Dianhydrogalactitol
Kintara Therapeutics, Inc.